@Article{ecn.2006.0044,
AUTHOR = {Joanna Iłżecka, Marek Iłżecki},
TITLE = {APRIL is increased in serum of patients with brain glioblastoma multiforme},
JOURNAL = {European Cytokine Network},
VOLUME = {17},
YEAR = {2006},
NUMBER = {4},
PAGES = {276--280},
URL = {http://www.techscience.com/ECN/v17n4/66140},
ISSN = {1952-4005},
ABSTRACT = {A PRoliferation-Inducing Ligand (APRIL) is a cytokine with the ability to induce tumorigenesis.
The aim of the study was to measure serum APRIL levels in patients with brain glioblastoma multiforme. Twenty
five patients with brain tumor and a control group of 25 subjects took part in the study. APRIL was measured by
the enzyme-linked immunosorbent method. The study showed increased APRIL levels in the serum of patients
with brain glioblastoma multiforme compared to the control group (p < 0.05). However, there was no significant
difference in the level of this cytokine between groups of patients divided according to their clinical state and
tumor size (p > 0.05). Inflammation parameters such as C-reactive protein (CRP) and polymorphonuclear
leucocytes (PMN) were also increased in patients with brain tumor compared to controls (p < 0.05). There was a
significant correlation between APRIL and CRP and PMN (p < 0.05). Results from the study suggest that APRIL
may play a role in the pathogenesis of brain glioblastoma multiforme. It is possible that anti-APRIL therapy might
be useful in this disease. However, this cytokine cannot be regarded as a marker of tumor size or of severity of
the clinical condition of patients.},
DOI = {10.1684/ecn.2006.0044}
}